During the past decade, phylogenetic analysis of genetic sequence data from human immunodeficiency virus (HIV) strains in HIV-infected persons in different parts of the world has led to a greater understanding of the genetic diversity of HIV [1] . HIV type 1 (HIV-1) viruses have been organized into 3 major groups: group M (major group), including subtypes A-J; group O (outlier group), which does not have recognized subtypes; and, most recently, group N [2] . Although the significance of subtype and group designations on the epidemiologic, clinical, and diagnostic characteristics of HIV-1 viruses is not fully understood [3] , the occurrence of infections with group O HIV-1 viruses is of considerable interest, because HIV EIA kits do not consistently detect serologic responses to infections with group O viruses [4, 5] .
Most group O HIV-1 infections have been identified in Africa; much smaller numbers of infections have been identified in Europe [6] . The highest prevalence of HIV-1 group O infec-tions is in the Central African country of Cameroon [6, 7] , which is also the country of origin for the first reported case of group N HIV [2] . Serosurveillance in the United States of 1057 serum samples from high-and low-risk persons did not reveal any sample with serologic evidence of group O HIV-1 infection [8] . To further examine this issue, we used national HIV and AIDS surveillance data to distinguish persons living in the United States who, on the basis of their country of birth, might be at increased risk for infection with group O or group N HIV-1.
Methods
Health care providers are required to confidentially report AIDS cases to the state or local health department, and in 31 states cases of HIV infection with no AIDS-defining condition are reportable. From all states, these case reports, without personal identification information, are forwarded by state health departments to the Centers for Disease Control and Prevention (CDC). Case reports contain information on age, sex, race/ethnicity, date of diagnosis, residence at the time of diagnosis, country of birth, and risks for HIV transmission, which allow classification of cases into probable exposure categories [9] . We analyzed data for all persons aged у13 years who were reported to the CDC through 31 January 1997.
We defined persons at increased risk for HIV-1 group O infection as those who were reported with HIV or AIDS in the United States and whose country of birth in the HIV or AIDS case report was listed as an African country where HIV-1 group O infection or serologic evidence of HIV-1 group O infection had been reported in the medical literature as of March 1996 or a country bordering Cameroon, where the highest prevalence of HIV-1 group O infection has been reported. The countries were Cameroon, Chad, Congo, Equatorial Guinea, Gabon, Niger, Nigeria, Senegal, and Togo. In retrospect, these criteria also should select persons from the geographic region where the first group N infection was identified [2] .
Persons at increased risk for HIV-1 group O were contacted by their state or local health department and were asked to participate in a surveillance system to detect group O HIV-1 infections in the United States. Those who agreed were interviewed by use of a previously described questionnaire to collect information on risks for HIV infection [10] , and a blood sample was taken for determination of viral subtype at the CDC. Data were maintained confidentially in accordance with requirements for the protection of HIV/AIDS surveillance data.
Local health departments used standard surveillance practices to classify some persons at increased risk for HIV-1 group O infection as lost to follow-up. Typically, designation as lost to followup was made after, at a minimum, review of medical records and contact with the health care provider who knew the patient's most recent address. Other designations were as follows: deceased (determined by health department follow-up or by review of death registries); enrolled (persons who were located and consented to participate or those who were not located or who had died but for whom we had sufficient stored blood and whose consent for HIV testing and risk information were in the medical record); and refused (persons who were located but refused to participate). Risk for HIV infection was based on the surveillance hierarchy described elsewhere [9] ; for persons who did not report risk behaviors other than sexual contact but who reported heterosexual sex in Africa, the mode of transmission was considered to be heterosexual contact.
Polymerase chain reaction (PCR). HIV-1-specific PCR was done on uncultured peripheral blood lymphocytes. Blood (8 mL) was drawn into Vacutainer CP tubes and processed according to the manufacturer's instructions (Becton Dickinson, Franklin Lakes, NJ). Total cellular DNA was prepared by lysis of 6 4 ϫ 10 peripheral blood lymphocytes/mL in lysis buffer (10 mM Tris [pH 8.3]/0.05% Triton X-100), addition of 10 mg/mL proteinase K, incubation at 56ЊC for 1 h, and inactivation of proteinase K at 95ЊC for 10 min. env gp41 [11] , env C2V3 [11] , gag p17 [11] , and core p24 [12] PCR amplification conditions and primer sequences were as described elsewhere. The standard primers for env gp41 amplification were JH41 (5 -CAGCAGGWAGCACKATGGG, nt 7815-7833) and JH38 (5 -GGTGARTATCCCTKCCTAAC, nt 8382-8363) for first-round PCR; env27F (5 -CTGGYATAGTG-CARCARCA, nt 7878-7896) and Menv19R (5 -AARCCTCCT-ACTATCATTATRA; nt 8316-8297) for nested PCR. The nt numbers refer to positions in the reference strain HIV MN (accession no. M17449). Primers for C2V3 were MK369 and MK616 for primary PCR and primers MK650 and CO601 for nested PCR. The p17 gene primers were CL1028 and AB1033 for primary PCR and CL1029 and AB1032 for nested PCR.
Samples that could not be amplified by use of standard primers were tested by use of generic primers designed to detect all known groups of HIV-1, including group N HIV viruses [13] . In brief, amplification was carried out by use of gp40F1/gp41R1 and gp46F2/gp47R2 primer sets within gp41, which delineates a highly sensitive region for amplification of viral RNA/DNA from HIV-1-positive specimens representing the different subtypes of HIV-1 groups M, O, and N [13, 14] .
DNA sequencing and phylogenetic analysis. For DNA sequencing, we used the ABI Prism Dye Terminator Cycle Sequencing Reaction kit (Perkin Elmer, Foster City, CA) with AmpliTaq DNA polymerase FS and an automated sequencer (ABI model 373; Applied Biosystems, Foster City, CA). HIV-1 sequences were derived from the HIV env gp41 immunodominant region, C2V3, p17, and p24 regions. Both strands of the PCR products were sequenced directly. Direct sequencing of PCR-amplified fragments represents a consensus sequence or the predominate virus species present. Sequence data were analyzed by software (Sequencher 3.0; Gene Codes, Ann Arbor, MI). Nucleic acid sequences were trimmed to equivalent lengths and aligned with representative HIV-1 groups M, O, and N subtypes in the Los Alamos database. The neighborjoining method included in the Phylip 3.5c software package (University of Washington, Seattle) was used to construct the phylogenetic trees. Where available, the gp41 sequences obtained were used for phylogenetic analysis, which allows an accurate subtype determination, similar to that previously shown by C2V3 sequences [14] . We submitted 30 gp41 region DNA sequences (accession nos. AF096323-AF096350, AF197948, and AF197949) to GenBank.
Serotype determination. Serum or plasma from all specimens was evaluated by subtype-specific peptide serology [8] . For samples that were reactive in 12 subtype-specific peptide EIAs, we report the final serotype as multiply reactive. For samples that were reactive in either A or C peptide EIAs, we report the serotype as A/ C, because these serotypes are difficult to distinguish by serology [15] . The predictive value of a monoreactive serotype B result is good [15, 16] ; for samples classified as subtype B on the basis of peptide serology but for which nucleic acid amplification was not successful, the final subtype was considered B.
Results
Of 670,374 persons reported to the surveillance system with HIV or AIDS as of 31 January 1997, 155 persons were at increased risk for HIV-1 group O infection on the basis of reported country of birth (table 1) . Of the 126 persons with AIDS in the group, 51 had AIDS defined only by !200 CD4 T lymphocytes or !14 CD4 percent. There was some geographic clustering (61 cases were from New York or New Jersey) of the persons at increased risk for HIV-1 group O infection; there was no apparent temporal clustering of selected cases.
Of the 37 persons enrolled, 1 was deceased, but stored blood and consent for HIV testing and supplemental information by medical record review were available. For 1 person, it was determined after interview and blood draw that the country of birth was Zambia; however, because this person had behavioral risk with a person from 1 of the target countries, we included the specimen in the subtype analysis.
Enrollment rates were better for persons reported with HIV infection, not AIDS (62%), than for persons reported with AIDS (38%;
); for persons with AIDS, the proportions P = .002 of deceased, refusing, and lost to follow-up were greater than those for persons with HIV but not AIDS (table 1) . For enrolled persons with AIDS, 16 had AIDS defined only by immunologic criteria, and 7 had AIDS defined by opportunistic illnesses. For other demographic factors, there were no significant differences between enrolled and nonenrolled cases. For the 37 enrolled persons whose blood samples were analyzed, DNA PCR was successful for 32 (31 in gp41; 1 in c2/ v3) and unsuccessful with use of p17, p24, gp41, or c2/v3 primers for 4; for 1 person the sample was insufficient for an attempt at amplification. Phylogenetic analysis of the 32 sequences indicated that 30 were infected with HIV-1 group M, 2 were infected with group O, and none was infected with group N virus. Among subjects with group M infections, 16 were infected with subtype A, 7 with subtype C, 3 with subtype B, and 1 each with subtypes D, F2, G, and recombinant A/J (figure 1). Two of the specimens represented very recently identified subtypes: J (96USSN48) [17] and subcluster F2 within subtype F (96USCM48) [18] . The phylogenetic relationship of the gp41 sequences of the 31 sequence strains and reference strains is shown in figure 1 . Complete peptide serology and other sequence data are shown in table 2.
Of the 4 specimens for which amplification was not successful, 2 were considered to be infected with subtype B HIV-1 from the results of monoreactive serology with subtype B peptides. The remaining 2 nonamplifiable samples and the sample that was insufficient for amplification were considered untypeable but were considered non-O, non-N, on the basis of the results of subtype serology and PCR with group N primers [13] .
The 5 persons infected with subtype B strains of HIV-1 and the 32 persons infected with non-B strains of HIV-1 were similar in age, sex, country of birth, and case status (HIV infection vs. AIDS) at the time of report to the health department. There were no statistically significant differences, although statistical power was low because of the low number of subtype B infections.
Discussion
The results of this surveillance for group O HIV-1 suggest that even among persons at highest risk for group O infection, on the basis of country of birth, HIV-1 group O is not common in the United States. Furthermore, we found no case of HIV-1 group N. However, persons born in Central and West Africa, where group O is most prevalent, were commonly infected with non-B subtypes of HIV-1, indicating that they were probably infected with HIV in Africa or by a person infected in Africa.
HIV-1 group O infections are of concern in the United States because the HIV EIA kits used to screen blood donations do not consistently detect HIV-1 group O infections [4, 5] . Because of this concern, the Food and Drug Administration (FDA) instituted a temporary exclusion criterion for prospective blood donors with epidemiologic links to Central and West Africa [20] and will require new submissions of HIV EIA kits to detect group O infections [21] . Given the apparently low prevalence of group O infection in the United States [8] and the measures taken by the FDA, the risk to the blood supply from this strain is probably minimal. Few cases of infection with sequence-confirmed non-B strains of HIV-1 have been reported in the United States [15, 19, [22] [23] [24] [25] . More than 100 potential non-B HIV-1 infections have been defined by peptide serology only; however, peptide serology alone may not always accurately classify group M subtypes [16, 26] . Our study documents an additional sequence-confirmed 29 non-B cases (3 of these cases have been reported [19, 23] ), including 2 recently recognized subtypes J and F2 [17, 18] .
Although not initially designed to detect group N infections, our sampling method would be expected to identify persons with epidemiologic links to the area in Central Africa associated with the first group N case [2] , and our sequencing would probably have documented any such divergent HIV strain if it was present. For the 2 non-B samples that did not amplify by DNA PCR or RNA PCR by standard or group N primers, RNA PCR may have been unsuccessful because RNA concentrations may have been very low because of antiretroviral therapy. Group N cannot be ruled out in these samples.
Non-B subtypes of HIV-1 have been proposed to have significance for transmission [27] [28] [29] , clinical course [30, 31] , disease monitoring by HIV-RNA concentration [32] [33] [34] [35] [36] , clinical care [37] , detection by HIV EIA [38] , and vaccine development [39] . However, many of these issues are not fully resolved [3, 40] . The importance of subtypes in the epidemic was recently reviewed from an epidemiologic perspective [40] .
Surveillance for HIV subtypes by use of a targeted country of birth approach offered a means of identifying persons at highest risk for HIV-1 group O infection but has some difficulties and limitations. Although initial contact with subjects was made through their health care providers, persons not born in the United States may be reluctant to participate in studies of HIV conducted by state and local health departments because of concerns about immigration status. Furthermore, a large proportion of the potential participants with AIDS who were reported to the surveillance system were dead or lost to follow-up at the time of our study. In addition, significantly more persons with HIV infection, but not AIDS, were located and consented to participate than those with AIDS. Persons with group O or group N infection, negative HIV-EIA results [2, 4, 5] , and no AIDS-defining opportunistic illness would not be included in the HIV/AIDS Reporting System database, decreasing the sensitivity of this subtype surveillance. However, persons with negative or unknown HIV EIA results may be reported to the surveillance system on the basis of certain opportunistic illnesses alone [41] . For these reasons, this subtype surveillance represents the minimum estimate of the occurrence of group O and group N infections in the United States.
Physicians should be aware that persons with epidemiologic contacts with Central and West Africa may be infected with a non-B HIV-1 subtype and should order and interpret RNA concentration determinations in these patients in light of this possibility. Physicians caring for persons with clinical evidence of AIDS, especially those with behavioral risk for HIV infection or epidemiologic links to Africa, but for whom EIA results are negative, should consider the possibility of infection with group O or group N and contact their state or local health depart-ment for assistance with the diagnosis of group O or group N infection.
